Introduction
============

Tuberculosis (TB) causes more than 1.4 million deaths annually and is the second leading cause of death due to an infectious disease after human immunodeficiency virus (HIV).[@b1-clep-6-405] The morbidity and mortality associated with TB is especially pronounced in low-income developing countries where malnutrition, crowded living conditions, and lack of TB control measures makes the disease a serious public health burden.[@b1-clep-6-405]--[@b3-clep-6-405] In high-income industrialized nations, the epidemiology of TB has changed, with immigrants from endemic countries now constituting a major proportion of new TB cases.[@b4-clep-6-405],[@b5-clep-6-405] Several studies have established specific risk factors and predictors of short-term case fatality rates, but the long-term prognosis of patients with TB is still poorly described.[@b6-clep-6-405]--[@b8-clep-6-405]

In order to assess whether long-term mortality is affected in patients who have survived a TB episode compared with the background population, we conducted a nationwide population-based cohort study to determine long-term mortality and causes of death in patients diagnosed with pulmonary (PTB) or extrapulmonary tuberculosis (EPTB). To investigate potential family-related risk factors, we also estimated mortality in siblings of the patients with TB.

Materials and methods
=====================

Ethics statement
----------------

This study is a registry-based cohort study involving data from various Danish national registries. All data were anonymized before any statistical analysis was performed and the study was approved by the Danish Data Protection Agency.

Study design
------------

This study was conducted as a population-based nationwide cohort study. The study populations were all PTB and EPTB patients registered in Denmark in the period 1977--2008 and a cohort from the background population individually matched on age and sex. Outcomes were time to death and to cause-specific death. The risk of these outcomes was further estimated in the siblings of the patients with TB and compared with that of the siblings of the comparison cohort.

Setting
-------

The population of Denmark was 5.08 million on January 1, 1977 and 5.48 million on January 1, 2008.[@b9-clep-6-405] The incidence of TB decreased in the study period from 12/100.000 in 1977 to 6/100.000 in 2008.[@b10-clep-6-405],[@b11-clep-6-405] Denmark has an estimated HIV prevalence of 0.07%.[@b12-clep-6-405] Throughout the study period, Danish citizens had access to free health care and antituberculosis medication. The Bacille Calmette Guerin vaccine was phased out of the Danish national childhood vaccination program in the period 1976--1980. All culture-based TB diagnostics are centralized at the International Reference Laboratory of Mycobacteriology at Statens Serum Institut, Copenhagen, Denmark.

Data sources
------------

The unique 10-digit personal identification number assigned to all Danish citizens at birth or immigration was used to avoid multiple registrations and to track individuals in the following registries.

### Danish Tuberculosis Registry

All TB patients diagnosed in Denmark are notified to the Danish Tuberculosis Registry by the treating physician and by the International Reference Laboratory of Mycobacteriology. This notification is mandatory for all patients initiating anti-TB treatment. The Danish Tuberculosis Registry contains data on anatomical localization of TB, ethnic origin, date of diagnosis, residence, and microbiologic data.

### Danish National Patient Registry

The Danish National Patient Registry (DNPR) contains information on all patients discharged from Danish somatic hospitals since 1977.[@b13-clep-6-405] Data includes dates of admission and discharge diagnosis coded by the International Classification of Diseases, Eighth Revision (ICD-8), until the end of 1993 and the Tenth Revision (ICD-10) thereafter. From this registry, date of first admission with PTB or EPTB was extracted.

### Danish Civil Registration System

The Danish National Patient Registry (DCRS) was established in 1968 and contains information on date and place of birth and death, sex, immigration and/or emigration for all Danish residents.[@b14-clep-6-405]

### Danish Registry of Causes of Death

The Danish Registry of Causes of Death contains data from all Danish death certificates since 1943 and is updated to December 31, 2009.[@b15-clep-6-405] Causes of death are coded according to ICD-8 until the end of 1993 and according to ICD-10 thereafter. The physician can code one immediate cause of death followed by secondary and/or tertiary causes of death and finally one underlying (main) cause of death.

Study population
----------------

### PTB and EPTB patients

We included all individuals who fulfilled the following five criteria: notified to the Danish Tuberculosis Registry from January 1, 1977 until December 31, 2008; registered in the DNPR with a diagnosis of PTB (ICD-8 codes 011.00--013.00 and ICD-10 codes A15.0--17.0) or EPTB (ICD-8 codes 014.00--019.00 and ICD-10 codes A 18.0--20.0); notified to the Danish Tuberculosis Registry within 1 year of DNPR date of discharge; ≥16 years of age at time of diagnosis; and registered in the DCRS. EPTB was defined as TB of all anatomical localizations other than lungs and pleura, with the exception of tuberculous meningitis and intracerebral tuberculoma (a detailed study of this patient category has recently been published by Christensen et al)[@b16-clep-6-405] and patients diagnosed with miliary TB (to ensure uniform patient populations with sole organ involvement). Diagnosis was either microbiologically verified by positive culture, nucleic acid amplification, or direct microscopy, or based on clinical symptoms and/or radiology. The date of TB diagnosis was defined as the date of first admission for TB according to DNPR, and the index date as 1 year after TB diagnosis. Patients were excluded from the study population if they died, emigrated, or were lost to follow-up within the first year of TB diagnosis.

### Population comparison cohorts

For each TB patient, we identified all Danish citizens in the DCRS who were born in Denmark with the same birth date and sex as the patient and were alive and not diagnosed with TB on the index date of the respective patient. From this population, we randomly identified three individuals per TB patient who constituted the comparison cohort. The index date for the population controls was therefore the same as for the TB patient to whom they were matched.

### Siblings

From the DCRS, all siblings of the PTB patients and PTB population controls were identified who fulfilled the following criteria: full siblings; born after January 1, 1952, and alive and not younger than 16 years of age at the time of the patient's or control's index date. Less than 10% of siblings of individuals born before 1952 could be identified in DCRS, rising to 43% in the 1952 birth cohort and 96% for individuals born after 1958.[@b17-clep-6-405] EPTB siblings were not included due to inadequate study population size which did not allow for sibling mortality studies.

Comorbidity
-----------

A modified Charlson Comorbidity Index (CCI) score was used as a measurement of comorbidity and calculated from DNPR diagnoses prior to the first TB diagnosis.[@b18-clep-6-405] Three levels of comorbidity were defined: none (CCI score 0), low (CCI score 1--2), and high (CCI score \>3). As an alternative measure of comorbidity, data on in-hospital patient admissions in the 5 years prior to the date of TB diagnosis was extracted from the DNPR for all patients, population controls, and siblings. These data were subcategorized according to diagnostic categories based on discharge diagnosis.

Statistical analysis
--------------------

Time was calculated from index date to the date of death, emigration, loss to follow-up or December 31, 2009, whichever came first. Kaplan--Meier analyses were used to construct survival curves. All-cause mortality rate ratios (MRR), representing relative risk of death, and 95% confidence intervals (CIs) were calculated and stratified according to sex, age at time of diagnosis, ethnicity, and level of CCI score of the TB patient. Cause-specific MRRs were based on the underlying cause of death and categorized as listed in the Supplementary materials.

For siblings we computed time from January 1, 1977, or the index date of the respective patient or population control, whichever came last, until date of death, emigration, loss to follow-up, or December 31, 2009, whichever came first. Poisson regression analyses were used to calculate all-cause and cause-specific MRRs (adjusted for age and sex) for siblings of PTB patients compared with siblings of the PTB population controls and for PTB patients born after 1 January, 1952 compared with their respective siblings. Statistical Package for the Social Sciences version 15.0 for Windows (SPSS Inc., Chicago, IL, USA), R version 2.13.0 (R Foundation for Statistical Computing, Vienna, Austria), and Stata version 11 (StataCorp, College Station, TX, USA) were used for data analysis.

Results
=======

Characteristics of TB patient cohorts
-------------------------------------

We identified 11,258 TB patients of whom 6,402 PTB patients and 1,889 EPTB patients fulfilled the inclusion criteria ([Figure 1](#f1-clep-6-405){ref-type="fig"}). A total of 5,290 (82.6%) PTB patients and 1,713 (90.7%) EPTB patients were microbiologically verified. For both cohorts, the proportion of immigrants increased with calendar time ([Table 1](#t1-clep-6-405){ref-type="table"}). Due to the study design, the control cohorts were well matched with respect to age and sex, but PTB and EPTB patients had more comorbidity and had been hospitalized more frequently than their respective population control cohorts ([Table 1](#t1-clep-6-405){ref-type="table"}).

Characteristics of sibling cohorts
----------------------------------

A total of 1,990 siblings of PTB patients and 11,679 siblings of the PTB control cohort were identified. The PTB patients' siblings had slightly increased comorbidity, including TB, and more were HIV-positive compared with the siblings of the population control cohort ([Table 1](#t1-clep-6-405){ref-type="table"}).

Mortality in PTB patient population versus matched population controls
----------------------------------------------------------------------

A total of 2,388 (37.3%) PTB patients and 4,683 (24.4%) PTB population controls died during the study period. A Kaplan--Meier survival curve for the PTB cohort and their population control cohort is shown in [Figure 2](#f2-clep-6-405){ref-type="fig"}. An overall MRR of 1.86 (95% CI 1.77--1.96) was found for the PTB cohort ([Table 2](#t2-clep-6-405){ref-type="table"}).

When stratified by individual risk factors, a higher mortality was found in the PTB cohort for males (MRR 2.04; 95% CI 1.92--2.17) compared with females (MRR 1.61; 95% CI 1.48--1.75). The MRR decreased with increasing age at time of TB diagnosis and the relative risk of death increased with increased comorbidity ([Table 2](#t2-clep-6-405){ref-type="table"}). Danish-born PTB patients had a slightly higher risk of death (MRR 1.94; 95% CI 1.84--2.04) than immigrants (MRR 1.71; 95% CI 1.48--1.98).

The PTB patients had an increased risk of death from natural causes (infectious, malignant, respiratory, rheumatic, liver/pancreatic diseases, and diabetes) and also from unnatural causes of death (alcohol and drug abuse, injury, and poisoning; [Table 3](#t3-clep-6-405){ref-type="table"} and [Table S1](#SD1-clep-6-405){ref-type="supplementary-material"}). The increased risk of malignant diseases in PTB patients was mainly driven by cancers of the respiratory tract, esophagus, breast, and hematologic system.

Mortality in EPTB patient population versus matched population controls
-----------------------------------------------------------------------

A total of 515 (27.3%) EPTB patients and 1,379 (24.3%) EPTB population controls died during the study period. A Kaplan--Meier survival curve for the EPTB cohort and their respective population control cohort is shown in [Figure 2](#f2-clep-6-405){ref-type="fig"}. An overall MRR of 1.24 (95% CI 1.12--1.37) was found for the EPTB cohort ([Table 2](#t2-clep-6-405){ref-type="table"}). When stratified by individual risk factors, the MRR was found to decrease with increasing age at time of TB diagnosis. Also, the MRR increased with higher levels of comorbidity. The relative risk of death was not found to differ significantly when data were stratified by sex and ethnicity. The EPTB patients had an increased risk of death due to infectious, gastrointestinal, and genitourinary diseases, diabetes, and gastrointestinal and hematologic neoplasms ([Table 3](#t3-clep-6-405){ref-type="table"} and [Table S1](#SD1-clep-6-405){ref-type="supplementary-material"}).

Mortality in PTB patient population versus their siblings
---------------------------------------------------------

Compared with their respective siblings, the PTB patients had a significantly increased relative risk of death (MRR 3.55; 95% CI 2.57--4.91). In the stratified analyses we observed an increased risk of death in all subgroups ([Table 2](#t2-clep-6-405){ref-type="table"}). As all siblings were born after January 1, 1952, for comparison we calculated MRR for PTB patients born in the same period compared with their respective control cohort (MRR 4.62; 95% CI 3.85--5.57). Compared with their siblings, the PTB patients were at increased risk of death from infectious diseases (MRR 10.56; 95% CI 2.33--47.83), malignant neoplasms (MRR 2.71; 95% CI 1.15--6.37), and cardiovascular, respiratory, and gastrointestinal diseases ([Table 3](#t3-clep-6-405){ref-type="table"}).

Mortality in siblings of PTB patient population versus siblings of PTB control population
-----------------------------------------------------------------------------------------

The siblings of the PTB patients had a more than twofold excess mortality compared with siblings of the PTB control cohort ([Table 2](#t2-clep-6-405){ref-type="table"}), and this was not substantially reduced after exclusion of siblings with a history of TB (MRR 1.99; 95% CI 1.48--2.69), data not shown in tables. In the stratified analyses, an increased relative risk of death (MRR 2.45; 95% CI 1.76--3.40) was found for male siblings of PTB patients compared with male siblings of PTB controls.

Compared with siblings of the population controls, the siblings of the PTB patients had a significantly increased risk of death from infectious diseases (MRR 10.53; 95% CI 1.76--63.00), mental disorders, including alcohol and/or drug abuse (MRR 4.66; 95% CI 2.90--10.37), and gastrointestinal diseases (MRR 4.17; 95% CI 1.82--9.53, [Table 3](#t3-clep-6-405){ref-type="table"}).

Discussion
==========

In this nationwide, population-based cohort study, we observed an almost two-fold increased long-term mortality in PTB patients compared with an age-matched and sex-matched population comparison cohort. Increased relative risk of death was mainly predicted by male sex, younger age, native citizenship, comorbidity, and HIV coinfection. Further, an increased mortality was observed in the siblings of PTB patients. An increased risk of death was also identified in EPTB patients, although smaller than for the PTB patients.

To our knowledge, this is the first study to investigate long-term mortality in TB patients in a nationwide, population-based, cohort study design including estimates of mortality in siblings of TB patients. Our study has several strengths. First, the centralized registration of TB patients in Denmark enabled us to identify a large cohort of TB patients over a more than 30-year period. Second, having a purely native Danish population control cohort excludes the possible confounding related to a mixed ethnic control cohort. Third, the high proportion of microbiologically verified TB cases minimized risk of misclassification. Fourth, the extracted data originated from Danish national registries with high coverage and long-term and complete follow-up, thus providing high validity. Finally, access to the Danish registries allowed us to generate well matched, population-based comparison cohorts and identify siblings of the patients and population comparison cohorts. We were not able to adjust for potential confounding from smoking, alcohol abuse, and socioeconomic factors which may partly explain the observed excess mortality. We did not have access to patient files and were therefore not able to account for clinical parameters and treatment regimes. Also, our results are derived from a high-income setting with a low incidence of TB and HIV, and may not be comparable with settings of developing nations with a high incidence of HIV and drug-resistant TB.

Several studies have identified age, male sex, comorbidity, diabetes, HIV, and native citizenship as risk factors for active TB and short-term mortality in TB patients.[@b19-clep-6-405],[@b20-clep-6-405] We identified the same factors, except age, to be risk factors for increased long-term relative risk of death. The relative risk of death was highest in the younger age categories which may seem counterintuitive, but reflects the fact that the absolute risk of death is highest in the older background population, and increased mortality in the older TB patients thereby leads to a minor impact on relative risk of death.

Both PTB and EPTB patients were at increased risk of death due to TB, which is in accordance with a study from the UK which found TB to be responsible for 21% of all deaths during a 14-year follow-up.[@b20-clep-6-405] Both our cohorts were also at increased risk of death due to diabetes, a disease associated with not only an increased risk of TB but also increased mortality in TB patients; two retrospective US cohort studies both reported more than a six-fold increased mortality in diabetic TB patients compared with nondiabetic controls.[@b21-clep-6-405],[@b22-clep-6-405] With increasing use of biologic disease-modifying antirheumatic drugs, patients with rheumatic diseases are at increased risk of TB infection;[@b23-clep-6-405] this is reflected in our results, with PTB patients exhibiting more than a two-fold increased risk of death due to underlying rheumatic disease.

The epidemiologic evidence that alcohol abuse and exposure to cigarette smoke increase the risk of active TB is strong.[@b24-clep-6-405],[@b25-clep-6-405] The prevalence of alcohol abuse disorders among TB patients in developed countries ranges from 10% to 50%,[@b26-clep-6-405]--[@b30-clep-6-405] and it has been estimated that almost one third of Danish PTB patients suffer from alcohol abuse and one in ten from drug abuse.[@b31-clep-6-405],[@b32-clep-6-405] This is supported in our data on in-hospital admissions in the 5 years prior to TB diagnosis, where admissions linked to alcohol abuse were significantly more frequent among the PTB patients compared with population controls. Further, lower socioeconomic status is associated with active transmission of TB among native Danes.[@b33-clep-6-405] We observed an increased risk of long-term mortality in PTB patients from chronic lung diseases and lung cancer, alcohol and drug abuse, and gastrointestinal diseases, particularly liver-related. Also, the risk of death was increased in the siblings of these patients. Our data thereby underlines the fact that conditions related to tobacco, alcohol and drug abuse, immune suppression, and socioeconomic factors are not only risk factors for contracting TB and short-term mortality, but also are main determinants of long-term mortality.

Compared with PTB patients, we observed only minor increased risk of death in the EPTB patients, which supports previous results of lower case fatality rates among patients with EPTB.[@b19-clep-6-405] Also, the findings point toward less impact from tobacco, alcohol, and drug abuse.

We found a significantly increased risk of death due to malignant neoplasms in the PTB patient group compared with population controls. This excess mortality was primarily driven by an increased prevalence of deaths due to cancers of the airways, esophagus, breast and hematopoietic system. The majority of these subcategories have been strongly associated with smoking, alcohol abuse, and immunodeficiency.[@b34-clep-6-405]--[@b39-clep-6-405] A recent population-based cohort study from Taiwan that included 5,657 TB patients and 23,984 controls found a statistically significant increased incidence of lung cancer in the years after TB infection (269 per 100,000 person-years) compared with population controls (153 per 100,000 person-years).[@b40-clep-6-405]

The siblings of the PTB patients were at markedly increased risk of death compared with the siblings of the population controls and appeared to be at increased risk of death due to infectious and gastrointestinal diseases and alcohol and drug abuse. This high excess mortality among the siblings of PTB patients indicates that the excess long-term mortality among PTB patients cannot solely be attributed to an effect of TB infection, but must also be influenced by other family-associated, behavioral, and/or socioeconomic-related factors. We presume that these associations are explained by the fact that alcohol and drug abuse clusters in families and also leads to increased risk of TB as well as death due to infectious and gastrointestinal diseases. However, the MRR of PTB patients born after January 1, 1952 was almost twice that of their siblings, indicating that specific risk factors are also present in the PTB patient cohort and increase their mortality, although part of this excess mortality can be reflected in the younger age of the siblings. Studies have shown that growing up in an environment of low socioeconomic status increases the risk of death later in life;[@b41-clep-6-405],[@b42-clep-6-405] hence, one explanation might be that the patients and siblings share the same low socioeconomic status during childhood and are thus at increased risk of death in adulthood. Genetic predisposition to death from infectious diseases[@b43-clep-6-405] has been proposed along with evidence of increased genetic host susceptibility to acquiring infectious diseases such as TB.[@b44-clep-6-405]--[@b47-clep-6-405]

Our study has several clinical implications. It emphasizes that, in high-income settings, PTB patients suffer from substantially increased long-term mortality compared with EPTB patients and compared with the background population. Furthermore, it establishes that classical risk factors for active TB and short-term mortality are also the main risk factors for long-term mortality, and that PTB patients are at a significantly increased risk of dying from conditions related to tobacco, alcohol, and drug abuse and immune suppression. The study underlines the importance of addressing lifestyle and socioeconomic risk factors to substantially reduce long-term mortality in PTB patients.

Supplementary materials
=======================

Detailed subcategorization of causes of death according to ICD-8 and ICD-10 diagnosis codes
-------------------------------------------------------------------------------------------

The 18 categories of specific underlying causes of death were specified by the International Classification of Diseases, Eighth Revision (ICD-8), codes for the years 1977--1993 and the International Classification of Diseases, Tenth Revision (ICD-10), codes for 1994--2006. For infectious diseases, the codes were 000--134.99/A00--B99; cancer 140--209/C00--C96; blood/immune diseases 280--289.99/D50--D89; endocrine diseases 240--279.09/E00--E90; mental and behavioral disorders, including those due to psychoactive substance use and inebriation 290--315/F00--F99; nervous system diseases 320--358.09/G00--G99; diseases of the sensory organs 360--389.99/H00--H59; cardiovascular diseases 390--458.99/I00--I99; respiratory diseases 460--519.99/J00--J99; digestive system diseases 520--577.99/K00--K93; skin diseases 680--709.99/L00--L99; rheumatic diseases 710--738.09/M00--M99; genitourinary diseases 580--629.99/N00--N99; neonatal/congenital disorders 740--779.99/P00--Q99; pregnancy-related diseases 630--678.09/O00--O99; injury/poisoning 800--999/S00--T98, V, W, X, Y; ill-defined causes 780--796.99/R00--R99; and no cause of death reported.

###### 

Detailed cause-specific mortality rate ratios in PTB and EPTB patients compared with population controls, Denmark, 1977--2008

                                                                  PTB cohort   EPTB cohort                                               
  --------------------------------------------------------------- ------------ ------------- -------- --------------- ----- ----- ------ -------------
  Infectious diseases                                             156          31            18.38    12.50--27.02    14    8     5.79   2.43--13.80
   Tuberculosis and HIV/AIDS                                      135          3             164.33   52.34--515.92   10    0            
   Other infectious diseases                                      21           28            2.95     1.66--5.24      4     8     1.89   0.55--6.46
  Malignant neoplasms                                             530          1,242         1.56     1.41--1.73      118   334   1.17   0.95--1.44
   Malignant neoplasms of lip, oral cavity, and pharynx           28           22            4.65     2.66--8.12      0     7            
    Lip, oral cavity                                              0            0                                                         
    Tongue, palate, parotid gland                                 18           14            4.70     2.34--9.44                         
    Tonsils and oropharynx                                        4            4             3.65     0.91--14.60                        
    Nasopharynx                                                   0            0                                                         
    Hypopharynx                                                   2            3             2.43     0.41--14.57                        
    Unspecified cancer of the ear, nose, throat                   4            1             14.61    1.63--130.69                       
   Malignant neoplasms of digestive organs                        128          349           1.34     1.10--1.65      34    72    1.56   1.04--2.35
    Esophagus                                                     29           31            3.42     2.06--5.67      1     12    0.28   0.04--2.12
    Stomach                                                       17           44            1.41     0.81--2.47      6     6     3.31   1.07--10.26
    Small intestine                                               1            3             1.22     0.13--11.70     0     1            
    Colon                                                         33           126           0.96     0.65--1.40      10    29    1.14   0.56--2.34
    Rectum                                                        17           54            1.15     0.67--1.98      7     6     3.86   1.30--11.48
    Liver and gallbladder                                         13           30            1.58     0.83--3.03      3     3     3.31   0.67--16.39
    Pancreas                                                      16           55            1.06     0.61--1.85      6     14    1.42   0.54--3.69
    Unspecified gastrointestinal cancer                           2            6             1.22     0.25--6.03      1     1            
   Malignant neoplasms of respiratory and intra-thoracic organs   191          303           2.30     1.92--2.76      25    72    1.15   0.73--1.81
    Nasal cavity and middle ear                                   0            1                                                         
    Larynx                                                        12           11            3.98     1.76--9.03                         
    Lungs (including trachea)                                     171          278           2.25     1.86--2.72                         
    Pleura, mediastinum and other ill-defined sites               8            13            2.25     0.93--5.42                         
   Malignant neoplasms of bone and articular cartilage            1            3             1.22     0.13--11.70     1     1     3.31   0.21--52.88
   Melanoma and other malignant neoplasms of skin                 3            17            0.64     0.19--2.20      1     7     0.47   0.06--3.84
   Malignant neoplasms of breast                                  27           63            1.57     1.00--2.46      10    23    1.44   0.68--3.02
   Malignant neoplasms of female genital organs                   13           57            0.83     0.46--1.52      5     31    0.53   0.21--1.37
   Malignant neoplasms of male genital organs                     24           100           0.88     0.56--1.37      7     20    1.16   0.49--2.74
   Malignant neoplasms of urinary tract                           21           74            1.04     0.64--1.68      5     28    0.59   0.23--1.53
   Malignant neoplasms of central nervous system                  7            32            0.80     0.35--1.81      2     4     1.65   0.30--9.03
   Malignant hematologic neoplasms                                37           87            1.55     1.06--2.28      15    25    1.98   1.05--3.76
    Myeloma                                                       3            16            0.68     0.20--2.35      0     4            
    Lymphoma                                                      11           21            1.91     0.92--3.97      4     10    1.32   0.41--4.22
    Leukemia                                                      23           50            1.68     1.03--2.75      11    11    3.31   1.43--7.63
   Malignant neoplasms of other and ill-defined sites             50           125           1.46     1.05--2.03      10    43    0.75   0.38--1.49
    Benign neoplasms                                              0            7                                      2     1            
  Hematologic diseases                                            10           15            2.43     1.09--5.42      1     3     1.10   0.11--10.60
  Endocrine diseases                                              67           123           1.99     1.48--2.68      17    35    1.61   0.90--2.87
   Diabetes mellitus                                              56           92            2.22     1.59--3.10      15    25    1.98   1.05--3.76
  Psychiatric disorders                                           108          142           2.78     2.16, 3.57      8     27    0.98   0.45, 2.16
   Caused by alcohol and/or drugs                                 87           41            7.75     5.35, 11.23                        
   Other psychiatric disorders                                    21           101           0.76     0.47, 1.21                         
  Neurologic diseases                                             21           73            1.05     0.65, 1.71      9     14    2.13   0.92, 4.91
  Cardiovascular diseases                                         573          1761          1.19     1.08, 1.31      191   582   1.09   0.92, 1.28
  Respiratory diseases                                            353          432           2.98     2.59, 3.43      40    141   0.94   0.66, 1.33
   Acute infections of the upper respiratory tract                5            7             2.61     0.83, 8.22      0     0            
   Pneumonia and bronchitis                                       79           135           2.14     1.62, 2.82      14    48    0.96   0.53, 1.75
   Chronic illness of the lower respiratory tract                 241          260           3.38     2.84, 4.03      23    84    0.91   0.57, 1.44
   Diseases involving pleura, lung abscesses or edema             28           30            3.41     2.04, 5.70      3     9     1.10   0.30, 4.07
  Gastrointestinal diseases                                       178          210           3.10     2.53, 3.78      27    43    2.08   1.28, 3.36
   Liver disease                                                  113          62            6.66     4.88, 9.07      6     17    1.17   0.46, 2.96
   Esophagus, stomach, duodenum                                   14           64            0.80     0.45, 1.42      7     14    1.65   0.67, 4.10
   Inflammatory bowel disease                                     0            4                                      0     0            
   Ileus, diverticulitis, abscess, peritonitis                    25           41            2.23     1.35, 3.66      8     8     3.31   1.24, 8.81
   Pancreas and gall-bladder disease                              22           22            3.65     2.02, 6.59      3     1     9.92   1.03, 95.39
   Other gastrointestinal disease, including hemorrhage           4            17            0.86     0.29, 2.55      3     3     3.31   0.67, 16.39
  Dermatologic diseases                                           0            2                                      2     2     3.31   0.47, 23.48
  Rheumatic diseases                                              12           17            2.58     1.23, 5.40      1     8     0.41   0.05, 3.31
  Genitourinary diseases                                          22           78            1.03     0.64, 1.65      12    16    2.48   1.17, 5.24
  Injury or poisoning                                             150          219           2.50     2.03, 3.08      27    72    1.24   0.80, 1.93
  Not classified elsewhere                                        155          244           2.32     1.90, 2.84      32    79    1.34   0.89, 2.02
  Unknown                                                         51           89            2.09     1.48, 2.95      14    15    3.09   1.49, 6.40
  Congenital cause of death                                       2            5                                      1     0            
  Pregnancy related death                                         0            0                                      1     0            

**Abbreviations:** CI, confidence interval; EPTB, extrapulmonary tuberculosis; MRR, mortality rate ratio; PTB, pulmonary tuberculosis; HIV, human immunodeficiency virus; AIDS, acquired immune deficiency syndrome.
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![Kaplan--Meier survival curves.\
**Notes:** Graphs depict long-term mortality in patients (dashed line) with PTB (**A**), and EPTB (**B**), compared with population controls (solid line), Denmark, 1977--2008.\
**Abbreviations:** EPTB, extrapulmonary tuberculosis; PTB, pulmonary tuberculosis.](clep-6-405Fig2){#f2-clep-6-405}

###### 

Characteristics of PTB and EPTB patient cohorts, population comparison cohorts, and sibling cohorts

                                                           PTB patients        PTB population controls   Siblings of PTB patients   Siblings of PTB population controls   EPTB patients       EPTB population controls
  -------------------------------------------------------- ------------------- ------------------------- -------------------------- ------------------------------------- ------------------- --------------------------
  Total number, n (%)                                      6,402 (25.0)        19,206 (75.0)             1,990 (14.6)               11,679 (85.4)                         1,889 (25.0)        5,667 (75.0)
  Males, n (%)                                             3,855 (60.2)        11,565 (60.2)             1,055 (53.0)               6,244 (53.5)                          816 (43.2)          2,448 (43.2)
  Immigrants, n (%)                                        2,326 (36.3)        0                         405 (20.4)                 0                                     1,242 (65.7)        0
  Observation time (total), years                          64,212              234,484                   19,268                     12,449                                20,339              67,272
  Observation time, median (IQR), years                    8.1 (3.7--14.1)     10.5 (5.5--17.2)          8.3 (4.1--13.3)            9.7 (5.4--14.2)                       9.3 (4.8--14.7)     10.4 (5.9--15.8)
  Observation time (total), years, Danes                   40,398                                                                                                         7,291               
  Observation time, median (IQR), years, Danes             7.8 (3.4--14.2)                                                                                                9.1 (4.6--16.4)     
  Observation time (total), years, immigrants              23,814                                                                                                         13,047              
  Observation time, median (IQR), years, immigrants        8.7 (4.3--13.8)                                                                                                9.4 (5.0--13.8)     
  Lost to follow-up during study period, n (%)             79 (1.2)            4 (0.01)                  7 (0.4)                    5 (0.01)                              34 (1.8)            2 (0.001)
  Emigrated during study period, n (%)                     281 (4.4)           204 (1.1)                 54 (2.7)                   198 (1.7)                             158 (8.4)           62 (1.1)
  Age at diagnosis, median (IQR), years                    42.8 (30.1--58.6)   42.8 (30.1--58.6)         31.7 (25.3--38.4)          31.5 (24.0--38.2)                     38.8 (28.9--60.2)   38.8 (28.9--60.2)
  Age at diagnosis by age intervals, n (%)                                                                                                                                                    
   16--30 years                                            1,570 (24.5)        4,710 (24.5)              889 (44.7)                 5,043 (43.2)                          540 (28.6)          1,620 (28.6)
   31--60 years                                            3,357 (52.4)        10,071 (52.4)             1,101 (55.3)               6,636 (56.8)                          874 (46.3)          2,622 (46.3)
   \>61 years                                              1,475 (23.0)        4,425 (23.0)              0                          0                                     475 (25.1)          1,425 (25.1)
  Patients diagnosed by decade, n (%)                                                                                                                                                         
   1977--1986                                              2,026 (31.6)        6,078 (31.6)                                                                               548 (29.0)          1,644 (29.0)
    Immigrants, n (%)                                      383 (18.9)          0                                                                                          168 (30.7)          0
   1987--1996                                              1,500 (23.4)        4,500 (23.4)                                                                               463 (24.5)          1,389 (24.5)
    Immigrants, n (%)                                      605 (40.3)          0                                                                                          326 (70.4)          0
   1997--2008                                              2,876 (44.9)        8,628 (44.9)                                                                               878 (46.5)          2,634 (46.5)
    Immigrants, n (%)                                      1,338 (46.5)        0                                                                                          748 (85.2)          0
  Age at diagnosis by decade, median (IQR), years                                                                                                                                             
   1977--1986                                              52.6 (34.7--65.9)   52.6 (34.7--65.9)                                                                          57.6 (36.3--70.4)   57.6 (36.3--70.4)
   1987--1996                                              41.2 (29.7--57.6)   41.2 (29.7--57.6)                                                                          36.3 (27.2--60.6)   36.3 (27.2--60.6)
   1997--2008                                              39.5 (28.9--51.5)   39.5 (28.9--51.5)                                                                          34.6 (28.1--46.0)   34.6 (28.1--46.0)
  Modified Charlson Comorbidity Index, n (%)                                                                                                                                                  
   None (score 0)                                          5,498 (85.9)        17,744 (92.4)             1,897 (95.3)               11,254 (96.4)                         1,680 (88.9)        5,231 (92.3)
   Low (score 1--2)                                        791 (12.4)          1,340 (7.0)               85 (4.3)                   385 (3.3)                             177 (9.4)           408 (7.2)
   High (score≥3)                                          113 (1.8)           122 (0.6)                 8 (0.4)                    40 (0.3)                              32 (1.7)            28 (0.5)
  Hospital admission in 5 years prior to TB                                                                                                                                                   
  Total patients, n (%)                                    2,677 (41.8)        5,589 (29.1)              660 (33.2)                 3,695 (31.6)                          871 (46.1)          1,854 (32.7)
   Infectious diseases                                     176 (2.7)           171 (0.9)                 55 (2.8)                   116 (1.0)                             58 (3.1)            59 (1.0)
   Pulmonology                                             426 (6.7)           403 (2.1)                 50 (2.5)                   255 (2.2)                             61 (3.2)            131 (2.3)
   Endocrinology                                           133 (2.1)           192 (1.0)                 16 (0.8)                   82 (0.7)                              43 (2.3)            51 (0.9)
   Gastroenterology                                        491 (7.7)           834 (4.3)                 77 (3.9)                   369 (3.2)                             134 (7.1)           246 (4.3)
   Psychiatry                                              225 (3.5)           116 (0.6)                 29 (1.5)                   91 (0.8)                              9 (0.5)             37 (0.7)
   Cardiovascular                                          320 (5.0)           824 (4.3)                 38 (1.9)                   166 (1.4)                             88 (4.7)            227 (4.0)
   Alcohol-related                                         152 (2.4)           51 (0.3)                  10 (0.5)                   24 (0.2)                              2 (0.1)             9 (0.2)
   Injury or poisoning                                     677 (10.6)          1,105 (5.8)               158 (7.9)                  704 (6.0)                             106 (5.6)           306 (5.4)
   Neurology                                               90 (1.4)            167 (0.9)                 20 (1.0)                   97 (0.8)                              20 (1.1)            56 (1.0)
  Malignant neoplasm prior to study inclusion, n (%)       248 (3.9)           565 (2.9)                 17 (0.9)                   97 (0.8)                              61 (3.2)            190 (3.4)
  HIV diagnosis before or at time of TB diagnosis, n (%)   107 (1.7)           28 (0.001)                9 (0.5)                    14 (0.1)                              18 (1.2)            6 (0.001)
  Medical history of TB before study inclusion, n (%)      0                   0                         163 (8.2)                  17 (0.1)                              0                   0

**Abbreviations:** EPTB, extrapulmonary tuberculosis; HIV, human immunodeficiency virus; IQR, interquartile range; PTB, pulmonary tuberculosis; TB, tuberculosis.

###### 

All-cause mortality rate ratios in PTB and EPTB patients, population controls, and siblings, Denmark, 1977--2008

                                                          PTB cohort      EPTB cohort     Siblings (n=1,990) of PTB patients versus siblings (n=11,679) of PTB controls; all born after January 1, 1952   PTB patients (n=1,019) versus their respective siblings (n=1,990); all born after January 1, 1952                                                                                                        
  ------------------------------------------------------- --------------- --------------- --------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------- --------------- -------------------- ---------- ---------- ------------------ ----------- ---------- ------------------
  Overall                                                 2,388 (37.3%)   4,683 (24.4%)   1.86 (1.77--1.96)                                                                                               515 (27.3%)                                                                                         1,379 (24.3%)   1.24 (1.12--1.37)    74 (3.7)   206(1.8)   2.16(1.62-2.87)    110(10.8)   74 (3.7)   3.55(2.57-4.91)
  Overall for individuals born after January 1, 1952      271 (8.4)       193 (2.0)       4.62 (3.85--5.57)                                                                                                                                                                                                                                                                                                        
  **MRR stratified on individual risk factors**                                                                                                                                                                                                                                                                                                                                                                    
  Sex                                                                                                                                                                                                                                                                                                                                                                                                              
   Females                                                812             1,757           1.61 (1.48--1.75)                                                                                               299                                                                                                 789             1.24 (1.09--1.42)    16         65         1.53 (0.86-2.73)   30          16         6.95(3.46-13.94)
   Males                                                  1,576           2,926           2.04 (1.92--2.17)                                                                                               216                                                                                                 590             1.23 (1.05--1.43)    58         141        2.45(1.76-3.40)    80          58         2.86(1.98-4.12)
  Age at diagnosis (years)                                                                                                                                                                                                                                                                                                                                                                                         
   16--30                                                 87              106             2.71 (2.04--3.59)                                                                                               16                                                                                                  20              2.61 (1.35--5.04)    21         68         2.09(1.27-3.44)    29          21         2.93 (1.63-5.28)
    0--10 years observation time                          12              18              2.19 (1.05--4.55)                                                                                               5                                                                                                   4               4.09 (1.10--15.25)                                                                   
    \> 10 years observation time                          0               1               n/a                                                                                                             0                                                                                                   0               n/a                                                                                  
   31--60                                                 1,104           1,464           2.80 (2.59--3.03)                                                                                               140                                                                                                 310             1.50 (1.23--1.83)    53         138        2.17(1.54-3.08)    81          53         3.88 (2.63-5.72)
    0--10 years observation time                          500             306             5.87 (5.09--6.77)                                                                                               36                                                                                                  73              1.64 (1.10--2.44)                                                                    
    \>10 years observation time                           184             198             3.44 (2.81--4.20)                                                                                               20                                                                                                  29              2.39 (1.35--4.22)                                                                    
   \>60                                                   1,197           3,113           1.57 (1.47--1.68)                                                                                               359                                                                                                 1,049           1.15 (1.02--1.29)    0          0          n/a                0           0          n/a
    0--10 years                                           1,079           2,032           2.23 (2.07--2.40)                                                                                               266                                                                                                 680             1.32 (1.14--1.52)                                                                    
    observation time                                                                                                                                                                                                                                                                                                                                                                                               
    \>10 years observation time                           613             2,128           1.38 (1.26--1.50)                                                                                               188                                                                                                 593             1.15 (0.98--1.36)                                                                    
  Ethnicity                                                                                                                                                                                                                                                                                                                                                                                                        
   Native Danes                                           2,119           4,147           1.94 (1.84--2.04)                                                                                               429                                                                                                 1,158           1.27 (1.13--1.42)    72         206        2.38(1.78-3.18)    105         72         3.45 (2.48\^.80)
   Immigrants[b](#tfn3-clep-6-405){ref-type="table-fn"}   269             536             1.71 (1.48--1.98)                                                                                               86                                                                                                  221             1.26 (0.98--1.62)    2          0          n/a                5           2          5.85(1.12-30.61)
  Modified Charlson                                                                                                                                                                                                                                                                                                                                                                                                
  Comorbidity Index                                                                                                                                                                                                                                                                                                                                                                                                
   Score 0                                                1,857           3,689           1.80 (1.70--1.90)                                                                                               407                                                                                                 1,119           1.18 (1.06--1.33)                                                                    
   Score 1                                                460             902             2.20 (1.96--2.46)                                                                                               90                                                                                                  234             1.46 (1.15--1.86)                                                                    
   Score 2                                                71              92              4.22 (3.09--5.75)                                                                                               18                                                                                                  26              3.11 (1.70--5.67)                                                                    

**Notes:**

Adjusted for sex and age

immigrant patients compared with their Danish population controls.

**Abbreviations:** CI, confidence interval; EPTB, extrapulmonary tuberculosis; MRR, mortality rate ratio; n/a, not applicable; PTB, pulmonary tuberculosis.

###### 

Cause-specific mortality rate ratios in PTB and EPTB patients, population controls, and siblings, Denmark, 1977--2008

                                                                                PTB cohort   EPTB cohort   Siblings of PTB patents versus siblings of PTB controls   PTB patients versus their respective siblings                                                                                      
  ----------------------------------------------------------------------------- ------------ ------------- --------------------------------------------------------- ----------------------------------------------- ----- ----- ------ ------------- ---- ---- ------- ------------- ---- ---- ------- --------------
  Infectious diseases                                                           156          31            18.38                                                     12.50--27.02                                    14    8     5.79   2.43--13.80   7    2    10.53   1.76--63.00   11   7    10.56   2.33--17.83
  Neoplasms[b](#tfn6-clep-6-405){ref-type="table-fn"}                           530          1,242         1.56                                                      1.41--1.73                                      118   334   1.17   0.95--1.44    13   54   1.32    0.67--2.61    13   13   2.71    1.15--6.37
   Malignant neoplasms of lip, oral cavity, and pharynx                         28           22            4.65                                                      2.66--8.12                                      0     7                                                                            
   Malignant neoplasms of digestive organs                                      128          349           1.34                                                      1.10--1.65                                      34    72    1.56   1.04--2.35                                                      
   Malignant neoplasms of respiratory and intrathoracic organs                  191          303           2.30                                                      1.92--2.76                                      25    72    1.15   0.73--1.81                                                      
   Malignant neoplasms of bone and articular cartilage                          1            3             1.22                                                      0.13--11.70                                     1     1                                                                            
   Melanoma and other malignant neoplasms of skin                               3            17            0.64                                                      0.19--2.20                                      1     7     0.47   0.06--3.84                                                      
   Malignant neoplasms of breast                                                27           63            1.57                                                      1.00--2.46                                      10    23    1.44   0.68--3.02                                                      
   Malignant neoplasms of female genital organs                                 13           57            0.83                                                      0.46--1.52                                      5     31    0.53   0.21--1.37                                                      
   Malignant neoplasms of male genital organs                                   24           100           0.88                                                      0.56--1.37                                      7     20    1.16   0.49--2.74                                                      
   Malignant neoplasms of urinary tract                                         21           74            1.04                                                      0.64--1.68                                      5     28    0.59   0.23--1.53                                                      
   Malignant neoplasms of central nervous system                                7            32            0.80                                                      0.35--1.81                                      2     4                                                                            
   Malignant neoplasms of thyroid and other endocrine organs                    0            3                                                                                                                       1     0                                                                            
   Malignant hematologic neoplasms                                              37           87            1.55                                                      1.06--2.28                                      15    25    1.98   1.05--3.76                                                      
   Malignant neoplasm of other and ill-defined sites                            50           125           1.46                                                      1.05--2.03                                      10    43    0.75   0.38--1.49                                                      
   Benign neoplasms                                                             0            7                                                                                                                       2     1                                                                            
  Hematologic diseases                                                          10           15            2.43                                                      1.09--5.42                                      1     3     1.10   0.11--10.60   0    3                          1    0            
  Endocrine diseases                                                            67           123           1.99                                                      1.48--2.68                                      17    35    1.61   0.90--2.87    1    4    1.76    0.20--15.75   3    1    5.41    0.56--52.29
  Psychiatric disorders (including those caused by alcohol and/or drug abuse)   108          142           2.78                                                      2.16--3.57                                      8     27    0.98   0.45--2.16    12   15   4.66    2.09--10.37   11   12   2.44    0.97--6.09
  Neurologic diseases                                                           21           73            1.05                                                      0.65--1.71                                      9     14    2.13   0.92\^.91     0    6                          1    0            
  Cardiovascular diseases                                                       573          1,761         1.19                                                      1.08--1.3 1                                     191   582   1.09   0.92--1.28    5    26   1.35    0.52--3.52    II   5    3.87    1.34--11.21
  Respiratory diseases                                                          353          432           2.98                                                      2.59--3.43                                      40    141   0.94   0.66--1.33    3    5    1.40    0.16--11.95   7    3    15.37   1.87--126.61
  Gastrointestinal diseases                                                     178          210           3.10                                                      2.53--3.78                                      27    43    2.08   1.28--3.36    10   17   4.17    1.82--9.53    25   10   6.49    2.80--15.05
  Dermatologic diseases                                                         0            2                                                                                                                       2     2     3.31   0.47--23.48   0    0                          0    0            
  Rheumatologic diseases                                                        12           17            2.58                                                      1.23--5.40                                      1     8     0.41   0.05--3.31    0    0                          1    0            
  Genitourinary diseases                                                        22           78            1.03                                                      0.64--1.65                                      12    16    2.48   1.17--5.24    0    1                          0    0            
  Injury or poisoning                                                           150          219           2.50                                                      2.03--3.08                                      27    72    1.24   0.80--1.93    12   54   1.57    0.84--2.93    14   12   2.00    0.92--4.32
  Not classified elsewhere                                                      155          244           2.32                                                      1.90--2.84)                                     32    79    1.34   0.89--2.02    0    9                          8    0            
  Unknown                                                                       51           89            2.09                                                      1.48--2.95                                      14    15    3.09   1.49--6.40    11   7    11.06   4.29--28.52   3    11   0.47    0.13--1.70
  Congenital cause of death                                                     2            5                                                                                                                       1     0                          0    3                          1    0            
  Pregnancy-related death                                                       0            0                                                                                                                       1     0                          0    0                          0    0            

**Notes:**

Adjusted for sex and age.

Detailed neoplasm subanalysis not performed for sibling study populations due to small case numbers.

**Abbreviations:** CI, confidence interval; EPTB, extra-pulmonary tuberculosis; MRR, mortality rate ratio; PTB, pulmonary tuberculosis.
